NYU Langone Health
Second dose of IV dexamethasone reduced pain associated with TKA
GRAPEVINE, Texas — Results showed patients undergoing total knee arthroplasty who received two perioperative doses of dexamethasone had significantly lower overall inpatient opiate consumption compared with patients who received one dose.
Data show ‘critical need’ for universal genetic testing of patients with breast cancer
Universal germline genetic testing benefited patients with breast cancer and their physicians in implementing effective precision treatments and personalized disease management, according to study results published in JAMA Network Open.
Personalized diet yields similar weight loss as low-fat diet at 6 months
Compared with a low-fat diet, a personalized diet targeting postprandial glycemic response did not lead to greater weight loss at 6 months among adults with abnormal glucose metabolism and obesity, according to study data.
Novel test may predict adverse events with, recurrence after immunotherapy
An experimental test may help predict which patients with cancer may develop disease recurrence after immunotherapy treatment, according to study results published in Clinical Cancer Research.
Speaker: Be an ally to women in medicine through mentorship
CHICAGO — To be an ally to women in medicine, it is important to value the importance of diversity, be cognizant of inequities, accept feedback on personal shortcomings and be a mentor to incoming physicians, according to a presenter here.
DIRECT
Directional (Hawkone, Medtronic) vs. orbital (Diamondback 360, Cardiovascular Systems Inc.) atherectomy system on athero-sclerotic plaque in peripheral artery disease.
Expanding education ‘paramount’ to improve psoriasis care for patients with skin of color
Although psoriasis therapies continue to expand and improve, patients with skin of color still face barriers in access to care and diagnosis, especially if physicians are not adequately trained to identify the condition in all skin types.
Timing of pembrolizumab makes a difference in resectable melanoma
Neoadjuvant pembrolizumab extended event-free survival compared with adjuvant-only administration of the anti-PD-1 therapy among patients with resectable melanoma, according to phase 2 study results presented at ESMO Congress.
Cell therapy doubles survival, response rates in advanced melanoma
A single infusion of tumor-infiltrating lymphocytes more than doubled PFS, OS and complete response rates compared with ipilimumab among patients with advanced, unresectable melanoma, study results presented at ESMO Congress showed.
Olaparib regimen extends survival for certain women with advanced ovarian cancer
Maintenance therapy with olaparib and bevacizumab extended survival for women with newly diagnosed advanced ovarian cancer with homologous recombination deficiency, according to study results.